Portal:CPTAC/Hallmark/Therapeutics

From WikiPathways

(Difference between revisions)
Jump to: navigation, search
(added WP3844)
(added WP3593)
Line 9: Line 9:
*[[Pathway:WP4301]] Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells
*[[Pathway:WP4301]] Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells
*[[Pathway:WP3844]] PI3K-AKT-mTOR signaling pathway and therapeutic opportunities
*[[Pathway:WP3844]] PI3K-AKT-mTOR signaling pathway and therapeutic opportunities
 +
*[[Pathway:WP3593]] MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma

Revision as of 20:18, 2 January 2019

  • Pathway:WP3672 LncRNA-mediated mechanisms of therapeutic resistance
  • Pathway:WP3640 Imatinib and Chronic Myeloid Leukemia
  • Pathway:WP3614 Photodynamic therapy-induced HIF-1 survival signaling
  • Pathway:WP3617 Photodynamic therapy-induced NF-kB survival signaling
  • Pathway:WP3879 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression
  • Pathway:WP1601 Fluoropyrimidine Activity
  • Pathway:WP3 Phytochemical activity on NRF2 transcriptional activation
  • Pathway:WP4357 NRF2-ARE regulation
  • Pathway:WP4301 Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells
  • Pathway:WP3844 PI3K-AKT-mTOR signaling pathway and therapeutic opportunities
  • Pathway:WP3593 MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma
Personal tools